Lewy body dementias

KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Oncology, Other Science, Mental Health, Research, Hospitals, Genetics, Science, Clinical Trials, Cardiology, Principal, Brain, Policy, White House Fellows, ALS, Auburn House, Business, Lewy body dementias, Foreign Policy, Georgetown University, Harvard Kennedy School, Public policy, Virology, Bristol Myers Squibb, MBBS, Autophagy, House, IND, MBA, Iraq War, St. Lawrence University, B cell, Louisiana House of Representatives, MCAS, Hematology, Mast cell activation syndrome, Representative, Bluebird bio

KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.

Key Points: 
  • KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
  • KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations – KFRX03, KFRX04, KFRX05, and KFRX06 – with patent life through 2037.
  • Ms. Finger, the Principal at Auburn House Consulting, LLC, serves on the Board of ADMA Biologics, Inc. and is an Advisor at Quantile Health.
  • She previously held Board positions at Decibel Therapeutics, Vascular Biogenics and served as Chief Commercial Officer at Bluebird Bio.

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Amnesia, Patient, Medical Subject Headings, Autopsy, Marketing, European Commission, Dementia, Agency, INN, Risk, Physician, ATC, Positron emission tomography, International, European, PET, Nausea, Nuclear medicine, Brain, Language, Gelastic seizure, Cancer, Flushing, Chronic pain, Radiation, Lewy body dementias, Amyloid, Select, Committee, Medicine, Diagnosis, Safety, Radiopharmaceutical, Risk management, Anatomy, Skin, IIA, Deficit spending, CHMP, Medical imaging

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Nation’s Leading Frontotemporal Dementia-Focused Organization Receives $600,000 Gift For Vital Research And Family Support

Retrieved on: 
Monday, December 4, 2023
Quality of life, Open Hand, Travel, Lewy body dementias, Drug discovery, Caregiver, Research, FTD, Person, Disease, Memory, Completionist, Aircraft pilot, Pharmaceutical industry

Received on Wednesday, November 29th, this gift will trigger matching funds for a drug discovery initiative, resulting in $200,000 in additional support for FTD research.

Key Points: 
  • Received on Wednesday, November 29th, this gift will trigger matching funds for a drug discovery initiative, resulting in $200,000 in additional support for FTD research.
  • This generous charitable donation will help to accelerate AFTD efforts in research and drug discovery.
  • “We are honored to preserve her legacy by supporting continued research on this devastating disease.
  • This vital program focuses both on finding ways to slow the progress of FTD, and on managing challenging symptoms of this disease.

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Pharmacokinetics, Vance DeGeneres, Efficacy, Lewy body dementias, EAP, Death, Progress, MAP, Abstract, Diagnosis, AMX0035, Biomarker, Poster, Publication, Medication, Pharmaceutical industry, Medical imaging, Vaccine, Amylyx Pharmaceuticals, ALS, Amyotrophy, PHOENIX, Safety

New data using a model for assessing mortality-adjusted progression (MAP) for clinical trials of ALS and encore posters will be presented.

Key Points: 
  • New data using a model for assessing mortality-adjusted progression (MAP) for clinical trials of ALS and encore posters will be presented.
  • Results from a post hoc analysis of the Phase 2 CENTAUR trial using this model are presented, which resulted in a nearly identical statistical outcome with increased precision as the primary analysis.
  • This poster provides an update on the progress made in developing a biomarker test that could make the diagnosis of ALS easier.
  • A copy of the abstract discussing the MAP model is published online in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration .

Synapticure Welcomes Joe Leinbach as Chief Operating Officer and Expands Coverage to Additional Neurological Conditions

Retrieved on: 
Wednesday, September 6, 2023
Net, Insurance, ER, Huntington's disease, Patient, Neurodegenerative disease, St. Louis Fed Financial Stress Index, Health, DC, Quality of life, Lou Gehrig, Neurology, Michael D. Leinbach, Lewy body dementias, Medicare, NPS, Genetic counseling, Alzheimer's disease, Parkinson's disease, Retirement Insurance Benefits, Physician, Growth, Entrepreneurship, Diagnosis, ALS, Mental health, FTD, Family, Psychiatry, Caregiver, Health care, Nursing, Pharmaceutical industry

CHICAGO, Sept. 6, 2023 /PRNewswire/ --  Synapticure, a virtual clinic transforming treatment and outcomes for individuals and their caregivers living with neurodegenerative diseases, announced Joe Leinbach has joined as the company's first Chief Operating Officer. Leinbach joins at a critical time for the company's expansion into additional neurodegenerative conditions including Alzheimer's and related Dementias, while creating new ways to expand patient access through innovative partnerships with health systems and health plans.

Key Points: 
  • A veteran of early stage value-based care innovators, Leinbach has driven growth and operational success in leadership roles at Cityblock Health and Evolent Health.
  • Joe will lead the company's next phase of growth and efforts to implement innovative models that directly benefit patients and partners.
  • Synapticure's services also include behavioral health (psychiatry and therapy), genetic counseling, in-home physical therapy/occupational therapy, and speech language therapy.
  • Patients and providers can sign up or refer patients to Synapticure for a free consultation at www.synapticure.com or call us at (855) 255-5917.

SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of the Clinical Utility of DISCERN at BRAINWeek 2023

Retrieved on: 
Tuesday, September 5, 2023
Research, Managed Care, Pharmaceutical, Mental Health, Medical Devices, Genetics, Clinical Trials, Science, Biotechnology, Medical Supplies, Practice Management, Health, Minimally invasive procedure, DISCERN, MI, Software-defined, PCP, Geriatrics, Neurology, CNS, Otorhinolaryngology, Lewy body dementias, Dementia, Physician, Practitioner, Diagnosis, Alzheimer's disease, AD, Autopsy, Disease, Medical imaging

Additionally, our poster entitled “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose AD” will demonstrate the important autopsy-validated clinical study of the DISCERN test and its unparalleled contribution to accurately inform physician decision-making.

Key Points: 
  • Additionally, our poster entitled “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose AD” will demonstrate the important autopsy-validated clinical study of the DISCERN test and its unparalleled contribution to accurately inform physician decision-making.
  • Results demonstrate that most physicians would routinely use the results of DISCERN and the test was an important attribute in physician decision-making.
  • “Our test results confirm the value of DISCERN and its positioning as a promising breakthrough for early AD diagnosis,” says Amato.
  • For more information, visit SYNAPS Dx at booth #119 at BRAINWeek 2023.

AFTD and ALS Association Launch Funding Opportunity for Digital Tool Development in ALS and Frontotemporal Dementia

Retrieved on: 
Thursday, May 11, 2023
Partnership, Travel, Biotechnology, C9orf72, Pathology, Research, Multimedia, RNA, Person, Movement, ALS Association, The, Lewy body dementias, Diagnosis, Digital, ALS, FTD, Medical imaging, Vaccine, Pharmaceutical industry

KING OF PRUSSIA, Pa., May 11, 2023 /PRNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) and The ALS Association are launching a funding opportunity to support collaborative development of digital assessment tools across two overlapping neurodegenerative disorders: frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS).

Key Points: 
  • KING OF PRUSSIA, Pa., May 11, 2023 /PRNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) and The ALS Association are launching a funding opportunity to support collaborative development of digital assessment tools across two overlapping neurodegenerative disorders: frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS).
  • If correctly designed and applied, digital assessment tools have the potential to expand research into, and strengthen care for, ALS and FTD.
  • Once considered separate neurodegenerative disorders, FTD and ALS are now recognized to have many commonalities at the molecular, cellular, and clinical levels.
  • "AFTD is proud to partner with The ALS Association to foster collaboration across the FTD and ALS research communities," Dr. Dacks added.

Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023

Retrieved on: 
Monday, April 3, 2023
PD, PAR, International Conference on Emerging Infectious Diseases, MD, Patient, SAN, Amyloidosis, Lewy body dementias, Alzheimer's disease, AD, VNAR, Conference, SBP-04 and SBP-07 mines, Liquor, Medical imaging

The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.

Key Points: 
  • The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.
  • AT-04 alone demonstrated brain penetration similar to other monoclonal antibodies that have shown clinical efficacy in Alzheimer's Disease.
  • AT-07, the conjugation of AT-04 to the Brain Shuttle, resulted in a 10-fold increase in mouse brain penetration versus AT-04.
  • Abstract Title: Development of Brain Shuttle Enabled AT-04, a Novel Peptibody That Binds Neuropathologic Fibrillar Aggregates

Amprion showcases SYNTap® Biomarker Test at AD/PD™ 2023 International Conference

Retrieved on: 
Monday, March 27, 2023
Alpha-synuclein, Myenteric plexus, LDT, PD, Multiple system atrophy, Doctor of Philosophy, The Michael J. Fox Foundation, DSM-IV codes, Approximation error, Lewy, Cerebrospinal fluid, Lewy body dementias, Dementia, Parkinson's disease, International Conference on Emerging Infectious Diseases, MJFF, MSA, Patient, SAN, Medicine, Laboratory developed test, Exhibition, Diagnosis, CSF, AD, Research, LBD, Synucleinopathy, Conference, Amprion, Medical imaging, Alzheimer's disease, Disease, MD

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1. Amprion's findings will be highlighted in one oral presentation on Friday, March 31st 16:50 CET in hall G4 during the Alpha-Synuclein, PD Mechanistic Aspects Symposium, and in three posters located within the exhibition hall. Please see below for more information. Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.

Key Points: 
  • Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.
  • "It is estimated that around 44 million people worldwide are living with Alzheimer's disease or a related form of dementia.
  • "Amprion is committed to positively impacting brain disease diagnosis, which will help accelerate life-saving drug development for patients suffering from these diseases.
  • SYNTap will also be presented in the context of three posters, located in the Exhibition Area for all conference days that the Exhibition is open:

Lewy Body Dementia Resource Center Introduces VIEWS FROM WITHIN: A Lewy Body Video Series

Retrieved on: 
Tuesday, March 21, 2023
Knowledge, Hallucination, Montefiore Medical Center, Dina Merrill, Caregiver, HIV, Face, DSM-IV codes, Muscular dystrophy, Physician, ALS, View from Within, Frontotemporal dementia, Lewy body dementias, Dementia, Cerebral palsy, Parkinson's disease, Patient, Diagnosis, Albert Einstein College of Medicine, Caregiver stress, LBD, Alzheimer's disease, Disease, Residential care, Love

NEW YORK, March 21, 2023 /PRNewswire/ -- Lewy Body Dementia Resource Center (LBDRC) has released their exclusive video series, VIEWS FROM WITHIN, presenting firsthand experiences of people living with Lewy body dementia (LBD), their caregivers, and expert physicians. Crucial information and personal experiences about little-known multiple symptoms and numerous stages are shared in order to heighten awareness of LBD's manifestations, and the difficulties families face in getting correct diagnosis and the ensuing challenging care.

Key Points: 
  • This New Video Series Reveals Firsthand Experiences of People Living with Lewy Body Dementia, Their Caregivers, and Expert Physicians
    NEW YORK, March 21, 2023 /PRNewswire/ -- Lewy Body Dementia Resource Center (LBDRC) has released their exclusive video series, VIEWS FROM WITHIN, presenting firsthand experiences of people living with Lewy body dementia (LBD), their caregivers, and expert physicians.
  • Lewy body dementia is the second most common form of progressive dementia after Alzheimer's disease and affects more than 1.4 million Americans.
  • Falcone Public Relations, board member of the Lewy Body Dementia Resource Center, and author of I Didn't See It Coming: Scenes of Love, Loss, and Lewy Body Dementia (Publication date October 3, 2023, by East End Press).
  • Views From Within:  A Lewy Body Video Series can be viewed on Lewy Body Dementia Resource Center's website at: